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Disease activityAbstract Aim of the work: Behc¸et’s disease (BD) is an inﬂammatory, systemic and chronic disor-
der with unknown etiology affecting multiple systems. Visfatin is a new adipokine with insulin-
mimetic properties and pro-inﬂammatory function. The serum visfatin levels were evaluated in
BD patients to investigate its role in the pathogenesis and clinical manifestations of the disease.
Patients and methods: Forty BD patients were recruited from the Behc¸et’s disease clinic at Shiraz
University of Medical Sciences in southern Iran and 40 healthy control subjects of matching age,
sex and body mass index (BMI) were also included. Serum visfatin level was measured using
ELISA.
Results: The 40 BD patients included 16 males and 24 females. Seventeen had active clinical
manifestations; 16 with oral ulcer, 5 with genital ulcer, 6 with arthritis and 2 with uveitis. The mean
age of the BD patients was 34.95 ± 9.6 years and mean BMI was 23.98 ± 4.44. There were no
signiﬁcant differences between cases (5.05 ± 3.05 ng/ml) and controls (4.72 ± 2.84 ng/ml) in the
visfatin level (p= 0.61). The difference in the visfatin level between patients with active and inactive
manifestations did not reach statistical signiﬁcance (6.13 ± 3.20 and 4.25 ± 2.73, respectively;
p= 0.07). There was no signiﬁcant difference according to the gender of the patients or the
presence of clinical manifestations.
42 S. Shenavandeh et al.Conclusion: In view of the results in this study, visfatin levels were not signiﬁcantly different
between cases and controls. There was a tendency to a higher level of serum visfatin in active
BD patients compared to the inactive cases; however, the difference was unremarkable.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Behc¸et’s disease (BD) is an inﬂammatory, systemic and chronic
disorder of unknown etiology affecting multiple systems with
an underlying immune-mediated vasculitis [1]. Central events
have been involved in the pathogenesis of BD such as cytokine
overproduction [2,3], oxidative stress [4] apoptosis [5] and
genetic polymorphisms [6]. The cause is not clear but seems
to be multifactorial, including humoral and cellular immune
system dysfunction, endothelial cell dysfunction and genetic
predisposition [7].
Classical form of Behc¸et’s disease presents with recurrent
oral and genital ulcers [7] and ocular involvement [8]. Other
systems and organs are involved which may lead to mucocuta-
neous, articular, neurological [9], vascular [10] and pulmonary
manifestations [11].
White adipose tissue produces a variety of proteins called
adipocytokines, with important roles in body metabolism
[12]. Many researchers have studied different adipocytokines
in other rheumatic diseases; in a study on RA patients, the
serum leptin level was signiﬁcantly higher than in the control
however, it did not signiﬁcantly correlate with any of the clin-
ical and laboratory parameters of disease activity [13]. There
was a highly statistically signiﬁcant increase in resistin levels
in systemic lupus erythematosus (SLE) patients being more
obvious in those with lupus nephritis and signiﬁcantly corre-
lated with the disease activity [14]. On studying different adi-
pocytokines in ankylosing spondylitis patients, serum
adiponectin was not elevated while the signiﬁcantly elevated
serum leptin level correlated with disease activity giving clue
to its role in the inﬂammatory process of the disease. However
the signiﬁcantly elevated serum resistin level did not correlate
with the disease activity [15].
One of the newly identiﬁed secreted adipocytokines is visf-
atin, which is secreted by the visceral fat and its plasma level
increases during obesity. It has insulin-mimetic effects in
metabolism of cultured cells and activates the insulin receptor
[12]. Visfatin also stimulates inﬂammatory cells like monocytes
and can induce increasing circulating levels of IL-6. It has been
considered as a new proinﬂammatory adipocytokine [16].
Originally, the enzyme nicotinamide phosphoribosyltransfer-
ase (NAMPT) was identiﬁed as pre-B cell colony enhancing
factor (PBEF) a presumptive cytokine-like protein involved
in subclinical inﬂammation [17]. Later the protein was
renamed visfatin, a visceral fat-derived adipocytokine believed
to mimic insulin action [18].
A few investigations have been carried out on visfatin levels
in Behc¸et’s disease although other adipokines like resistin and
leptin have been more thoroughly investigated and there are
some suggestions for their increased levels in BD [19–22]. In
a study on visfatin, it was shown to be higher in the rheuma-
toid arthritis (RA) and active Behc¸et’s patients [23]. In anotherstudy, it was lower in active and inactive BD patients com-
pared to the normal control group [24].
Previous studies have evaluated the visfatin level in immu-
nologic disorders like RA and showed it was signiﬁcantly
higher compared to the control subjects [16,25–27]. It is also
considered as a responsive marker to treatment [28]. In
patients with ankylosing spondylitis, baseline levels of adipo-
cytokines did not predict the change of disease activity or func-
tional ability [29]. In patients with systemic sclerosis, visfatin
has a potential role in the disease process; it may exert a direct
anti-ﬁbrotic effect on dermal ﬁbroblasts and an indirect effect
by promoting Th1 immune polarization [30]. Serum visfatin
was strongly associated with lupus nephritis in a study on
SLE patients and was considered a promising biomarker for
prediction of renal involvement in those patients [31].
In this study, we have evaluated the serum visfatin level in
BD patients to detect if it plays a role as a proinﬂammatory
marker in the pathogenesis and clinical manifestations of this
disorder.
2. Patients and methods
In the present study, we included 40 Behc¸et’s disease patients
who were 17–55 years old and were selected by a convenient
and sequential method from patients referred to the Behc¸et’s
clinic of Shiraz University of Medical Sciences and 40 healthy
subjects aged 19–58 years during 23 Oct. 2010 and 21 Apr
2011. All patients fulﬁlled the international diagnostic (ISG)
criteria for Behc¸et’s disease [32]. The patients with sepsis or
acute lung injury, patients using more than 7.5 mg of prednis-
olone, those with renal or liver insufﬁciency, metabolic diseases
and smoking ones (including current smokers or ex-smokers)
were excluded from the study. Patients with Behc¸et’s disease
and healthy subjects were matched for age, body mass index
(BMI) and sex.
Screening, demographic measurements and clinical assess-
ment were performed by a rheumatologist who was involved
in this research protocol. The study group received a checklist
with inclusion and exclusion criteria. A written informed con-
sent was signed by the patients and the data were registered
chronologically. The study was approved by the local ethics
committee of Shiraz University of Medical Sciences.
In patients included in this study, clinical activities were
assessed at the time of venipuncture, on the basis of active
signs and symptoms (oral ulcers, genital ulcers, eye lesions,
skin lesions, vascular lesions, active arthritis, and neurological
manifestations) during the preceding 2 weeks. Patients whose
clinical signs and symptoms worsened during 2 weeks before
sampling were considered to have active manifestations. All
samples were centrifugated to receive serum. Then samples
were kept in the refrigerator (80 C) in the autoimmune
research center of Shiraz University of Medical Sciences. The
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tion of visfatin in the serum of the patients and controls. This
assay was a sandwich Enzyme Linked-Immunosorbent Assay
(ELISA).
The statistical analysis was performed using the statistical
Package for Social Sciences, version 16.0 (SPSS-16). The
results were expressed as mean value ± standard deviation.
The Mann–Whitney U-test, Kruskal–Wallis test and Pearson
correlation test were applied. p-values < 0.05 were considered
statistically signiﬁcant.
3. Results
The 40 BD patients had a mean age of 34.95 ± 9.6 years
(ranging from 17 to 55 years), they were 16 males and 24
females (M:F 2:3) with a mean BMI of 23.98 ± 4.44. The 40
healthy control group had a mean age of 35.68 ± 8.3 years
(ranging from 19 to 58 years), and were 17 males and 23
females (M:F 1:1.4) with a BMI of 23.28 ± 3.32. Both patients
and controls had a matching age, gender ratio and BMI.
In the BD patients, the mean visfatin level was
5.05 ± 3.05 ng/ml (1.5–13.07 ng/ml) and in the healthy control
group was 4.72 ± 2.84 ng/ml and the difference between them
was insigniﬁcant (p= 0.61). The mean visfatin levels in the BD
patients were comparable between males (5.03 ± 3.8 ng/ml)
and females (5.06–2 ± 5 ng/ml).
There were 17 patients with the active clinical manifesta-
tions during blood sampling. In patients with active disease,
there were 16 with oral ulcer, 5 with genital ulcer, 6 with arthri-
tis, and 2 with uveitis. Differences in the serum visfatin levels
between patients with active and inactive clinical manifestations
approximated to the signiﬁcance levels (6.13 ± 3.2 ng/ml and
4.25 ± 2.73 ng/ml, respectively; p= 0.07) (Table 1).
In active patients, there were no signiﬁcant difference
between visfatin levels in patients with oral ulcer (p= 0.13),
genital ulcer (p= 0.88), arthritis (p= 0.73), and uveitis
(p= 0.79) compared to the patients without these
manifestations.
There was no signiﬁcant correlation between the BMI and
visfatin levels in the Behc¸et’s patients and control groups
(p= 0.88).Table 1 Serum visfatin level in patients with and without active cli
Clinical manifestation in Behc¸et’s disease patients (n= 40) N (
Active oral ulcers
Yes 16
No 24
Active genital ulcer
Yes 5 (1
No 35
Active arthritis
Yes 6 (1
No 34
Active uveitis
Yes 2 (5
No 38
Total active manifestations
Yes 17
No 234. Discussion
Visfatin is a newly discovered adipokine, with insulin-mimetic
properties and pro-inﬂammatory function. Along with other
adipokines, there are suggestions for their role in the patho-
genesis of inﬂammatory diseases whereas visfatin serum con-
centration was not associated with insulin resistance and
carotid atherosclerosis in selected rheumatic diseases, it was
higher in the RA and active BD patients [23].
There are other studies conducted on other adipokines like
resistin and leptin in Behc¸et’s disease. Yalc¸indag˘ and cowork-
ers have evaluated serum leptin levels in 57 BD patients com-
pared to 20 healthy subjects. They found a signiﬁcantly higher
serum leptin level and CRP in the patients. Interestingly,
serum leptin level was higher in patients with nonocular BD
compared to the ocular ones [33]. Kavuncu and coworkers in
their study included 28 male BD patients with ocular involve-
ment and 15 healthy subjects and measured their serum leptin
level. Even though the ESR was higher in the ocular Behc¸et’s
patients, the serum leptin level was insigniﬁcantly different
[20]. In the study of Pehlivan et al. the serum resistin, CRP,
and ESR levels were signiﬁcantly elevated in BD patients com-
pared with healthy controls. Patients with active BD also had
signiﬁcantly higher levels of these parameters than did patients
with inactive disease [22].
A previous study on visfatin and its role as a pro-
inﬂammatory marker in Behc¸et’s revealed that patients’ serum
visfatin levels in 58 BD patients were lower compared to
healthy controls and the levels in active patients were lower
in comparison with inactive ones, but this difference was not
signiﬁcant [24]. However, in another study on 30 BD patients
conducted by Ozgen et al. it was determined that serum visfa-
tin levels were higher in RA and active BD which are Th-1-
mediated diseases, but not in the SLE and SSc which are
Th2-mediated diseases [23].
In our study, serum visfatin level was not signiﬁcantly
different betweenpatientswithBehc¸et’s disease andhealthy con-
trol group. Although, a tendency toward a signiﬁcant difference
was achieved when the patients with active and inactive forms
of Behc¸et’s disease were compared for visfatin level (6.13 ±
3.2 ng/ml and 4.25 ± 2.73 ng/ml, respectively; p= 0.07).nical manifestations of Behc¸et’s disease at the time of sampling.
%) Visfatin level (ng/ml) mean ± SD p-Value
(40) 5.97 ± 3.2 0.12
(60) 4.4 ± 2.8
2.5) 5.78 ± 4.02 0.57
(87.5) 4.94 ± 2.95
5) 5.48 ± 3.03 0.71
(85) 4.97 ± 3.90
) 4.64 ± 3.76 0.85
(95) 5.07 ± 3.07
(42.5) 6.13 ± 3.20 0.07
(57.5) 4.25 ± 2.73
44 S. Shenavandeh et al.It is worth mentioning that replication of this study with a
higher number of cases is recommended and considering to
recruit more active cases. Also there was no signiﬁcant differ-
ence between different clinical manifestations including ocular
or non-ocular manifestations and levels of visfatin. Probably,
further studies on more patients with different active manifes-
tations will help to conﬁrm the results of this study.
As to the present work, it could be concluded that visfatin
levels were not different between cases and control groups.
Although there was no signiﬁcant difference between visfatin
levels in BD patients with active disease comparing to non
active ones, it should be considered to have a role in the path-
ogenesis, clinical manifestations and disease activity.
Conﬂict of interest
None.Acknowledgments
The present article was extracted from the thesis written by
Dr. Maryam Barkhordar and ﬁnancially supported by the
Shiraz University of Medical Science Grant number:
89-5411. The authors would like to thank Dr. Nasrin
Shokrpour at Center for Development of Clinical Research
of Nemazee Hospital for editorial assistance.References
[1] Rizzi R, Bruno S, Dammacco R. Behc¸et’s disease: an immune-
mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res
1997;27(4):225–32.
[2] Gheita TA, Raafat H, Khalil H, Hussein H. Serum level of
APRIL/BLys in Behc¸et’s disease patients: clinical signiﬁcance in
uveitis and disease activity. Mod Rheumatol 2013;23:542–6.
[3] El Menyawi M, Fawzy M, Al-Nahas Z, Edris A, Hussein H,
Shaker O, et al. Serum tumor necrosis factor alpha (TNF-a) level
in patients with Behc¸et’s disease: relation to clinical manifestations
and disease activity. Egypt Rheumatologist 2014;36(3):139–43.
[4] Mahgoub M, Raslan H, Assal H, Gheita T, Fikry I, Abd El-
Moniem M, et al. Oxidant/antioxidant status in patients with
Behc¸et’s disease. Maced J Med Sci 2010;3:37–42.
[5] Gheita TA, Bassyouni IH, Bassyouni RH. Plasma concentrations
of growth arrest speciﬁc protein 6 and the soluble form of its
tyrosine kinase receptor Axl in patients with systemic lupus
erythematosus and Behc¸et’s disease. J Clin Immunol
2012;32(6):1279–86.
[6] Gheita TA, Gamal SM, Shaker I, El Fishawy HS, El Sisi R,
Shaker OG, et al. Clinical signiﬁcance of serum interleukin-23
and A/G gene (rs17375018) polymorphism in Behc¸ets disease:
relation to neuro-Behc¸et, uveitis and disease activity. Joint Bone
Spine 2014, in press.
[7] Sakane T, Takeno M, Suzuki N, Inaba G. Behc¸et’s disease. N
Engl J Med 1999;341(17):1284–91.
[8] Khalil HM, Raafat HA, Azab NA, Haroun HE, Elgendi HA. The
role of intraocular methotrexate in the management of uveitis and
posterior segment involvement in Behc¸et’s disease patients. Egypt
Rheumatol 2015;37(3):113–8.
[9] Gheita TA, Samir H, Hussein H. Anti-annexin V antibodies in
neuro-Behc¸et patients: clinical signiﬁcance and relation to disease
activity. Int J Rheum Dis 2012;15(5):e124–6.
[10] Hassan S, Gheita T, Ghoneim S, Nasr L. Subclinical atheroscle-
rosis in Behc¸et’s disease. Turk J Rheumatol 2012;27(2):109–14.[11] Emad Y, Abdel-Razek N, Gheita T, el-Wakd M, el-Gohary T,
Samadoni A. Multislice CT pulmonary ﬁndings in Behc¸et’s
disease (report of 16 cases). Clin Rheumatol 2007;26(6):879–84.
[12] Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M,
Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that
mimics the effects of insulin. Science 2005;307(5708):426–30.
[13] Abdalla M, Effat D, Sheta M, Hamed WE. Serum leptin levels in
rheumatoid arthritis and relationship with disease activity. Egypt
Rheumatologist 2014;36(1):1–5.
[14] Elshishtawy H, Ibrahim SE, Helmi A, Farouk N, Elshinnawy
MA. Resistin in systemic lupus erythematosus: relation to lupus
nephritis and premature atherosclerosis. Egypt Rheumatologist
2012;34(4):137–46.
[15] Elolemy GG, Ganeb SS, Abou Ghanima AT, Abdelgwad ER.
Inﬂuence of adipocytokines and IL-6 on ankylosing spondylitis
disease activity and functional status. Egypt Rheumatologist
2013;35(2):65–70.
[16] Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M,
Niederegger H, et al. Visfatin, an adipocytokine with proinﬂam-
matory and immunomodulating properties. J Immunol
2007;178(3):1748–58.
[17] Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor
(PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc
Biol 2008;83:804–16.
[18] Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M,
Kishimoto K. Visfatin: a protein secreted by visceral fat that
mimics the effects of insulin. Science 2005;307:426–30.
[19] Yalc¸indag˘ FN, Kisa U, Batiog˘lu F, Yalc¸indag˘ A, Ozdemir O,
Cag˘layan O. Serum leptin levels in patients with ocular and
nonocular Behc¸et’s disease. Mediators Inﬂamm 2007;2007:31986.
[20] Kavuncu S, Koc¸ F, Kurt M, Eryu¨ksel B, Ortac¸ S, Ozdal P, et al.
Evaluation of serum leptin concentration in Behc¸et’s disease with
ocular involvement. Graefes Arch Clin Exp Ophthalmol
2005;243(11):1158–60.
[21] Evereklioglu C, Inalo¨z HS, Kirtak N, Doganay S, Bu¨lbu¨l M,
Ozerol E, et al. Serum leptin concentration is increased in patients
with Behc¸et’s syndrome and is correlated with disease activity. Br
J Dermatol 2002;147(2):331–6.
[22] Pehlivan Y, Onat AM, Okumus S, Kisacik B, Comez G, Comez
A, et al. The role of resistin in Behc¸et’s disease: a Turkish
experiment. Mod Rheumatol 2012;22(4):571–5.
[23] Ozgen M, Koca SS, Aksoy K, Dagli N, Ustundag B, Isik A.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Clin Rheumatol 2011;30(6):757–63.
[24] Sezen H, Okumus S, Pehlivan Y, Dilli I, Tarakciog˘lu M, Onat
AM. Visfatin levels in Behc¸et’s disease. Inﬂammation
2012;35(2):405–8.
[25] Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S,
et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of
inﬂammation in rheumatoid arthritis with proinﬂammatory and
matrix-degrading activities. Arthritis Rheum 2007;56(9):2829–39.
[26] Alkady EA, Ahmed HM, Tag L, Abdou MA. Serum and synovial
adiponectin, resistin, and visfatin levels in rheumatoid arthritis
patients. Relation to disease activity. Z Rheumatol
2011;70(7):602–8.
[27] Bao JP, Chen WP, Wu LD. Visfatin: a potential therapeutic target
for rheumatoid arthritis. J Int Med Res 2009;37(6):1655–61.
[28] Klaasen R, Herenius MM, Wijbrandts CA, de Jager W, van Tuyl
LH, Nurmohamed MT, et al. Treatment-speciﬁc changes in
circulating adipocytokines: a comparison between tumour necro-
sis factor blockade and glucocorticoid treatment for rheumatoid
arthritis. Ann Rheum Dis 2012;71(9):1510–6.
[29] Hulejova´ H, Levitova´ A, Kuklova´ M, Stochl J, Haluzı´k M,
Pavelka K, et al. No effect of physiotherapy on the serum levels
of adipocytokines in patients with ankylosing spondylitis. Clin
Rheumatol 2012;31(1):67–71.
[30] Masui Y, Asano Y, Shibata S, Noda S, Akamata K, Aozasa N,
et al. A possible contribution of visfatin to the resolution of skin
Serum visfatin in patients with Behc¸et’s disease 45sclerosis in patients with diffuse cutaneous systemic sclerosis via a
direct anti-ﬁbrotic effect on dermal ﬁbroblasts and Th1 polariza-
tion of the immune response. Rheumatology (Oxford)
2013;52(7):1239–44.
[31] Fouda N, Abaza N, El-Hilaly R, El Said HW, EL-kabarity RH.
Evaluation of visfatin in patients with systemic lupus erythema-
tosus: correlation with disease activity and lupus nephritis. Egypt
Rheumatologist 2012;34(1):9–17.[32] Criteria for diagnosis of Behc¸et’s disease. International Study
Group for Behc¸et’s Disease. Lancet 1990;335(8697):1078–80.
[33] Yalc¸indag FN, Yalc¸indag A, Batioglu F, Caglayan O, Kisa U,
Ozdemir O. Evaluation of serum resistin levels in patients with
ocular and non-ocular Behc¸et’s disease. Can J Ophthalmol
2008;43(4):473–5.
